Dallas, TX -- (ReleaseWire) -- 02/02/2015 -- The report " Polycystic Ovarian Syndrome - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for polycystic ovarian syndrome. Polycystic ovary syndrome is a situation in which a woman has an imbalance of female sex hormones. Symptoms of polycystic ovary syndrome include infertility, pelvic pain, baldness or thinning hair, acne and oily skin. Women's with polycystic ovary syndrome are at higher risk of diabetes, metabolic syndrome, heart disease and high blood pressure. Polycystic ovary syndrome treatment starts with an appropriate diagnosis.
t also reviews key players involved in the therapeutic development for polycystic ovarian syndrome and special features on late-stage and discontinued projects. Companies discussed in this polycystic ovarian syndrome pipeline review H1 2015 report include AstraZeneca PLC, Crinetics Pharmaceuticals, Inc., EffRx Pharmaceuticals S.A., Euroscreen S.A., Merck KGaA, Neurocrine Biosciences, Inc.
Click Here to read more
